Navigation Links
Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
Date:9/2/2008

tissue surrounding the tumor. Unrelated clinical studies on radiotherapy correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

Studies Revealed at AAPM

VU Medical Center's studies into the use of Varian RapidArc plans for brain metastases and other key tumor sites were showcased at this year's American Association of Physics in Medicine (AAPM) show in Houston in July. Delivered using a Varian linear accelerator and measured in a solid water phantom, the 25 resulting film measurements showed high agreement with calculations, the VU team concluded. "RapidArc accurately delivers the planned dose distributions," stated Dr. Wilko Verbakel, medical physicist at VU Medical Center.

Dr. Ben Slotman, head of the radiation oncology department of VU University medical center said the hospital, among the first in Europe to introduce Varian's RapidArc, began clinical treatments using this fast and efficient form of volumetric modulated arc therapy in early May and more than 20 patients have so far been treated using the capability. "In the first few months we used RapidArc to replace IMRT treatments for head & neck, brain and prostate tumors but from September onwards RapidArc will replace all conventional IMRT," said Dr. Slotman. "Treatment planning is at least as good, and sometimes even better, than with conventional IMRT and planning and delivery using RapidArc is significantly faster."

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of t
'/>"/>

SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
3. NIH grants $750,000 to develop device to determine temperature of neonates brain
4. InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
5. Scientists create colorful brainbow images of the nervous system
6. Mouse Brain or Impressionist Painting?
7. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
8. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
9. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to The Nebraska Medical Center
10. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
11. Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to Froedtert Hospital in Milwaukee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)JERUSALEM, Israel, December 2 Gamida Cell announced today,a feasibility study evaluating the preclinical (animal study) safety and,efficacy of a gene therapy product which combines technology from We
Breaking Biology Technology:Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
...esented at National Department of Labor Conference...nce,received the U.S. Department of Labor,s Recogn...ating America,s Workforce to Serve Emerging,Indust...loyment and,Training, Brent R. Orrell, presented t...programs from around the country that have achieve...
...Shandong, China, July 30 /Xinhua-PRNewswire-FirstC...n Board: CBPO) ("CBP," or the,"Company"), one of t...n the,People,s Republic of China ("PRC"), today an...inted Mr. Sean Shao, Dr. Jie Gan, and Dr. Tong-Jun... of Directors, and that it,has established an Audi...
...O, July 30 Neurocrine Biosciences,Inc. (Nasdaq: ...he quarter,ended June 30, 2008. For the second qua...21.0 million, or $(0.55) per share compared with a...for the same period in 2007. For the,six months, t...r $(1.10),per share, as compared to $52.1 million,...
Other Biology Technology:Workforce Alliance Receives U.S. Labor Department's Excellence Award 2Workforce Alliance Receives U.S. Labor Department's Excellence Award 3China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors 2China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors 3China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors 4Neurocrine Biosciences Reports Second Quarter 2008 Results 2Neurocrine Biosciences Reports Second Quarter 2008 Results 3Neurocrine Biosciences Reports Second Quarter 2008 Results 4Neurocrine Biosciences Reports Second Quarter 2008 Results 5Neurocrine Biosciences Reports Second Quarter 2008 Results 6Neurocrine Biosciences Reports Second Quarter 2008 Results 7Neurocrine Biosciences Reports Second Quarter 2008 Results 8Neurocrine Biosciences Reports Second Quarter 2008 Results 9
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Thomson Reuters Survey 3A Most Americans Support Public Option in Healthcare Reform Legislation but Are Skeptical Healthcare Will Improve in 2010 62501 1Thomson Reuters Survey 3A Most Americans Support Public Option in Healthcare Reform Legislation but Are Skeptical Healthcare Will Improve in 2010 62501 2Lombardis Shields leads special journal focused on tobacco research 62500 1Lombardis Shields leads special journal focused on tobacco research 62500 2Acculturation affects smoking cessation success among Latinos 10972 1Acculturation affects smoking cessation success among Latinos 10972 2
...- The Damon Runyon Cancer Research Foundation name... Scientific Advisory Committee review. The recipi...standing postdoctoral scientists conducting basic ...ies of leading senior investigators across the cou...encourage the nation,s most promising young invest...
...2007 (Aliso Viejo, California) Ossur, an emerging...llowing several acquisitions and a period of integ... Trauma has published the long-awaited results of ...Mayo Clinic. The study, Range-of-Motion Restrictio... Four Cervical Collars, finds that Ossurs products...
...nto the way in which parasites interact with each ...are likely to break out. , A group of scientists...our of infectious parasites in rabbits. The findin...cessfully when infectious cyclical diseases in hum... Universitys School of Biosciences, University of ...
Other Biology News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young investigators 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young investigators 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young investigators 4Mayo Clinic study: Ossur's collars superior in immobilization and reduction of pressure 2Can interacting pathogens explain disease patterns? 2
Propidium Iodide Solution [3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide] from CHEMICON
...e complete ready-to-use reagents for the isolation... formulated for the isolation of genomic DNA from ...ated for the isolation of genomic DNA from plants....used for restriction endonuclease digestion Southe...
Propidium Iodide from GeneTex
Death Check III Assay System (Caspase/Cell Viability) from Promega
Biology Products: